Day: August 5, 2020

BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™...

WALL, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that Clearent, LLC selected BIO-key’s PortalGuard IAM solution to secure customer self-enrollment, account recovery and online access to its banking applications. Clearent is one of the fastest-growing credit card processing companies, processing $14 billion in annual transaction volume for 45,000 plus merchants nationwide. Clearent customers will also benefit from the security and convenience of PortalGuard’s Single Sign-on functionality utilized by customers for frictionless access to the Clearent’s payment portal.Clearent opted to use PortalGuard to replace its prior identity application. BIO-key’s PortalGuard IAM solution offered...

HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead investigational drug candidate, seclidemstat. The European Patent Office (EPO) recently announced that the European Patent EP2744330, exclusively licensed to Salarius from the University of Utah Research Foundation, was issued on July 15, 2020. The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). Salarius intends...

– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) administered via transversus abdominis plane (TAP) field block in patients undergoing Cesarean section (C-section) have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours.This was a multicenter, randomized, double-blind study across 13...

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 MillionSecond Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 MillionBELBUCA and Symproic® Each Reach All Time High TRx Volume and Market ShareConference Call and Webcast Scheduled for 8:30 AM EST TodayRALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June 30, 2020, as well as the following operational and performance highlights.Key Business HighlightsTotal Company net revenue for the second quarter increased by 23% versus the prior year period to $36.6 million. This growth was driven...

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:The 2020 Wedbush PacGrow Healthcare Conference. The presentation will take place on Wednesday, August 12, 2020, at 10:20 AM ET.The 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Thursday, August 13, 2020, at 3:30 PM ET.Live webcasts of each presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay...

On the 5th of August 2020, ContextVision held an Extraordinary General Meeting in Stockholm.The Board’s proposal for adoption of new articles of association was approvedThe Board’s proposal for decision on the share split of the company’s share was approvedNo other matters were processed at the meeting.For further information, please contact:Ann-Charlotte Linderoth (CFO)tel +46 (0)8 7503550, e-mail ann-charlotte.linderoth@contextvision.se###About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.Our expertise is to develop powerful software products, based on proprietary technology and...

Today, August 5th 2020, Reykjavik Energy (OR) sold new bonds in the Green Bond series OR180255 GB. The new issue amounted to ISK 2,500 million nominal value and the bonds were sold at a yield of 1.23%.Fossar Markets managed the process on behalf of OR.For further information please contact:Ingvar Stefánsson, CFO, tel: +354 516 6100email: ingvar.stefansson@or.is Matei Manolescu, Markets, Fossar Markets, tel: +354 522 4008, email: matei.manolescu@fossarmarkets.com

Orkuveita Reykjavíkur lauk í dag, 05. ágúst 2020, stækkun á skuldabréfaflokknum OR180255 GB. Gefin voru út skuldabréf að nafnverði kr. 2.500 milljónir og seld á ávöxtunarkröfunni 1,23%.Fossar markaðir hafa umsjón með útgáfu og sölu skuldabréfanna sem og töku þeirra til viðskipta á markaði Nasdaq á Íslandi með sjálfbær skuldabréf.Nánari upplýsingar veita: Ingvar Stefánsson, framkvæmdastjóri Fjármála OR, sími 516-6100, netfang: ingvar.stefansson@or.isMatei Manolescu, Fossar markaðir, sími 522 4008, netfang: matei.manolescu@fossarmarkets.com

MANITOWOC, Wis., Aug. 05, 2020 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), is a provider of LED lighting systems and turnkey project implementation including installation and commissioning of fixtures, controls and IoT systems, ongoing system maintenance and program management, helping customers to digitize their business and reduce their carbon footprint. Today Orion reported results for its FY 2021 first quarter (Q1’21) ended June 30, 2020. Orion will hold an investor call today at 10:00 a.m. ET (9:00 a.m. CT) to review its results and outlook (call details below).HighlightsQ1’21 revenue decreased to $10.8M from $42.4M in Q1’20, reflecting temporary COVID-19 related project suspensions and delays in new project starts in the recent period, versus significant major account activity in the year...